Metformin use and mortality in patients with advanced chronic kidney disease: National, retrospective, observational, cohort study

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 8, 2015, Pages 605-614

  Hung, Szu Chun ^a   Chang, Yu Kang ^b   Liu, Jia Sin ^b   Kuo, Ko Lin ^a   Chen, Yu Hsin ^c   Hsu, Chih Cheng ^b,d   Tarng, Der Cherng ^e  

^a TZU CHI UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; METFORMIN; ANTIDIABETIC AGENT;

ADULT; ADVANCED CHRONIC KIDNEY DISEASE; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE DURATION; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG USE; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TAIWAN; VERY ELDERLY; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; FOLLOW UP; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; CREATININE; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938208500     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00123-0     Document Type: Article

References (36)

1. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011, 305:2532-2539.
2. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012, 380:807-814. for the Alberta Kidney Disease Network.
3. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UK Prospective Diabetes Study (UKPDS) Group.
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
5. Standards of medical care in diabetes: 2013. Diabetes Care 2013, 36(suppl 1):S11-S66. American Diabetes Association.
6. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998, 338:265-266.
7. Richy FF, Sabidó-Espin M, Guedes S, Corvino FA, Gottwald-Hostalek U Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care 2014, 37:2291-2295.
8. Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010, 170:1892-1899. the Reduction of Atherothrombosis for Continued Health (REACH) registry investigators.
9. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach-update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015, 38:140-149.
10. Type 2 diabetes: the management of type 2 diabetes (NICE guidelines [CG87]) National Institute for Health and Care Excellence, (accessed May 15, 2015). http://www.nice.org.uk/guidance/cg87/chapter/guidance.
11. Heaf JG, van Biesen W Metformin and chronic renal impairment: a story of choices and ugly ducklings. Clin Diabetes 2011, 29:97-101.
12. Nye HJ, Herrington WG Metformin: the safest hypoglycaemic agent in chronic kidney disease?. Nephron Clin Pract 2011, 118:c380-c383.
13. Lalau JD, Arnouts P, Sharif A, De Broe ME Metformin and other antidiabetic agents in renal failure patients. Kidney Int 2015, 87:308-322.
14. Scheen AJ, Paquot N Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 2013, 39:179-190.
15. Cheng TM Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood) 2003, 22:61-76.
16. Hung SC, Kuo KL, Tarng DC, Hsu CC, Wu MS, Huang TP Anaemia management in patients with chronic kidney disease: Taiwan practice guidelines. Nephrology (Carlton) 2014, 19:735-739.
17. Hsu TW, Liu JS, Hung SC, et al. Renoprotective effect of renin-angiotensin system blockade among advanced chronic kidney disease non-dialyzed patients with hypertension and anemia. JAMA Intern Med 2014, 174:347-354.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
19. D'Agostino RB Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17:2265-2281.
20. Glynn RJ, Schneeweiss S, Stürmer T Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006, 98:253-259.
21. Iezzoni LI Risk adjustment for measuring healthcare outcomes 1997, Health Administration Press, Chicago. 2nd edn.
22. Fine JP, Gray RJ A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
23. Larsen S, Rabøl R, Hansen CN, Madsbad S, Helge JW, Dela F Metformin-treated patients with type 2 diabetes have normal mitochondrial complex I respiration. Diabetologia 2012, 55:443-449.
24. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011, 50:81-98.
25. Protti A, Fortunato F, Monti M, et al. Metformin overdose, but not lactic acidosis per se, inhibits oxygen consumption in pigs. Crit Care 2012, 16:R75.
26. Protti A, Lecchi A, Fortunato F, et al. Metformin overdose causes platelet mitochondrial dysfunction in humans. Crit Care 2012, 16:R180.
27. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002, 360:219-223.
28. Carré JE, Orban JC, Re L, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 2010, 182:745-751.
29. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014, 312:2668-2675.
30. Madiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014, 510:542-546.
31. He L, Wondisford FE Metformin action: concentrations matter. Cell Metab 2015, 21:159-162.
32. Kalantar-Zadeh K, Uppot RN, Lewandrowski KB Case records of the Massachusetts General Hospital: case 23-2013-a 54-year-old woman with abdominal pain, vomiting, and confusion. N Engl J Med 2013, 369:374-382.
33. Ekström N, Schiöler L, Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open 2012, 2:e001076.
34. Eppenga WL, Lalmohamed A, Geerts AF, et al. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. Diabetes Care 2014, 37:2218-2224.
35. Martin-Montalvo A, Mercken EM, Mitchell SJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun 2013, 4:2192.
36. Hung AM, Roumie CL, Greevy RA, et al. Comparative effectiveness on incident oral antidiabetic drugs on kidney function. Kidney Int 2012, 81:698-706.